Accession Therapeutics Limited
Sarah Brett has a diverse work experience in the events and operations management field. Sarah started their career as an Office Administrator at Champion Recruitment Agency in 2001 and then moved on to become an Events Manager at Elegant Cuisine from 2002 to 2005.
Sarah joined St.Hilda's College in 2005 as a Conference and Events Manager, where they successfully increased events income year on year and maintained a high level of repeat business. Sarah was also responsible for negotiating contracts, managing a small team, and planning and executing events and conferences. Sarah remained in this role until June 2021.
In June 2021, Sarah joined St. Hilda's College University of Oxford as an Events Team Manager. Sarah played an integral part in recruiting and establishing an Events Team as part of a department restructure. Under Sarah's management and training, the Events team organized and delivered high-quality internal and external events, resulting in increased events income. Sarah also met financial targets and secured new clients, positioning the department for potential future growth.
Sarah's most recent role is as an Operations Manager at Accession Therapeutics Limited, starting in November 2022. The details of their responsibilities and accomplishments in this role are not yet available.
Sarah Brett attended North Oxfordshire College and School of Art and Design from 1994 to 1995, where they completed a Foundation Course in Art and Design. Following this, they studied at Solent University from 1996 to 1999, earning a BA Hons degree in Fashion Design and Garment Production.
Accession Therapeutics Limited
Accession Therapeutics’ elegant Trocept platform has potential to treat some of the most intractable and widespread forms of cancer. Based in Oxford, UK, it is developing a pipeline of products to the early clinical trial stage. Led by Bent Jakobsen, PhD FMedSci, a pioneer of T cell receptor therapy for cancer, the team is highly experienced intaking immuno-oncology products to the clinic. Accession Therapeutics’ Trocept technology is based on over a decade’s work and has generated exceptional preclinical data.Accession Therapeutics’ proprietary technology incorporates cancer-tropic viruses, the first time that viruses have been genetically modified to exclusively target cancer cells.As non-cancerous cells are not targeted by Trocept, systemic toxicity is eliminated meaning the drugs can be delivered intravenously and traffic to the tumour.Trocept’s highly potent and local activity gives it potential in some of the hardest to treat and most widespread forms of cancer. This includes breast, cervical, colorectal, gastric, head and neck, lung, oral, ovarian and pancreatic cancer.